Related Experiment Videos
Polypharmacy in patients with schizophrenia
Robert E McCue1, Rubina Waheed, Leonel Urcuyo
1Department of Psychiatry, Woodhull Medical & Mental Health Center, 760 Broadway, Brooklyn, NY 11206, USA. mccuer@nychhc.org
The Journal of Clinical Psychiatry
|November 25, 2003
Summary
Schizophrenia treatment evolved, with more psychotropic medications and multiple antipsychotics prescribed by 2000. This shift correlated with fewer adverse drug reactions and improved patient outcomes in schizophrenia care.
Area of Science:
- Psychiatry
- Pharmacology
- Clinical Medicine
Background:
- Polypharmacy in schizophrenia treatment lacks robust evidence.
- Prescription practices for schizophrenia patients require examination over time.
Purpose of the Study:
- To analyze changes in psychotropic medication prescribing for schizophrenia patients between 1995 and 2000.
- To compare prescription patterns, adverse drug reactions, and patient outcomes.
Main Methods:
- Retrospective review of medical records for schizophrenia patients discharged in 1995 and 2000.
- Comparison of psychotropic medications, adverse drug reactions, and patient outcomes.
Main Results:
- Patients discharged in 2000 received more antidepressants, mood stabilizers, anxiolytics, and multiple antipsychotics compared to 1995.
- Antipsychotic polypharmacy increased significantly by 2000, with 15.9% of patients receiving more than one agent.
- Adverse drug reactions decreased, length of stay shortened, and community discharge rates increased in 2000.
Conclusions:
- Hospitalized schizophrenia patients received more complex psychotropic regimens by 2000.
- Increased polypharmacy, including multiple antipsychotics, coincided with reduced adverse events and better patient outcomes.
- Treatment shifts in schizophrenia care show positive correlations with improved safety and recovery indicators.